Equity Overview
Price & Market Data
Price: $0.419
Daily Change: +$0.0144 / 3.44%
Range: $0.405 - $0.43
Market Cap: $9,235,807
Volume: 55,358
Performance Metrics
1 Week: 13.55%
1 Month: -1.16%
3 Months: -50.12%
6 Months: -77.74%
1 Year: -79.36%
YTD: -48.53%
Company Details
Employees: 4
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.